Troriluzole in Adult Subjects With Spinocerebellar Ataxia


The purpose of this study is to compare the efficacy of Troriluzole (200mg once daily) versus placebo after 48 weeks of treatment in subjects with spinocerebellar ataxia (SCA).


  • Drug: Troriluzole
  • OR placebo 

For study details, including how the study is designed, please contact Stephen Gullet:


  • 18 - 75 years old
  • Subjects with a known or suspected diagnosis of the following specific hereditary ataxias: SCA1, SCA2, SCA3, SCA6, SCA7, SCA8 and SCA10;
  • Ability to ambulate 8 meters without human assistance (canes and other devices allowed)
  • Screening f-SARA total score ≥3;
  • Score of ≥1 on gait subsection of the f-SARA

Additional criteria apply, please contact Stephen Gullet for more information: 


18 to 65
65 and over



Can be done from home



Spinocerebellar Ataxia, Neurology, Ataxia

Principal Investigator

S.H. Subramony, MD



Contact Information


Be an Informed Participant

Before deciding to participate in a research study, take time to learn about clinical research, how it's conducted and your rights as a research participant. Following are some helpful resources from independent sources. Always remember that a clinical research study is research, not treatment.

Know Who to Contact

  • Eligibility: For questions about a specific study and who is eligible to participate, call or email the contact person listed for that study.
  • Your Rights: For questions about your rights as a research participant, contact the UF Institutional Review Boards at 352-273-9600.
  • Feedback: For general questions or feedback about study listings, email the UF Clinical and Translational Science Institute at

Other Resources

  • HealthStreet: Health-focused services, classes and events, and opportunities to participate in research.
  • Join a national registry of volunteers willing to be contacted about research studies.

For Research Teams